Harvard Bioscience (HBIO, Financial) experienced a significant stock movement with a 5.33% decline in its share price, which reached $2.42. The trading volume was 79,553 shares, with a turnover rate of 0.18% and a price fluctuation range of 5.46%.
In its latest financial report, the company reported a revenue of $23.10 million and a net loss of $2.93 million, translating to an earnings per share (EPS) of -$0.07. The gross profit stood at $11.89 million, with a price-to-earnings ratio of -9.74.
Analyst ratings show that both institutions providing coverage have issued a "buy" recommendation for HBIO, with no "hold" or "sell" recommendations made.
Within the medical devices sector, where HBIO operates, there was an overall decline of 0.90%. However, stocks such as Infusystems Holdings, Inc., Stereotaxis, Inc., and Ekso Bionics Holdings, Inc. performed well. Notably active stocks included Innovative Eyewear, Inc., AngioDynamics, and Predictive Oncology Inc., with turnover rates of 5.94%, 3.82%, and 1.42% respectively. Stocks with high price volatility included Innovative Eyewear Inc C/Wts 16/08/2027 (To Pur Com) Ser A, Innovative Eyewear, Inc., and Infusystems Holdings, Inc., with price swings of 44.54%, 13.71%, and 12.67% respectively.
Harvard Bioscience is a developer, manufacturer, and seller of specialized technology products and services for basic research, drug discovery, and preclinical testing. It predominantly sells scientific instruments used in life sciences research across North America, Europe, and China through direct and distribution channels. Major product brands include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab, with a significant portion of revenue originating from the United States.
